NCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
Clinical Trials
33 trialsNCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT03154281 2024-08-01
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT03312738 2024-01-23
BOLERO-5
Novartis
Phase 2 Completed
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT00934895 2023-09-18
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT01698918 2023-05-03
BOLERO-4
Novartis
Phase 2 Completed
NCT02120469 2022-07-05
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT02236572 2022-02-01
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Yale University
Phase 2 Terminated
NCT01931163 2021-07-20
NECTAR
The Methodist Hospital Research Institute
Phase 2 Completed
NCT01231659 2021-03-26
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT01783444 2021-02-26
BOLERO-6
Novartis
Phase 2 Completed
NCT01627067 2020-06-19
Exemestane-RAD001-Metformin
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03176238 2020-04-07
EVEREXES
Novartis
Phase 3 Completed
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01743560 2019-07-18
4EVERUK
Novartis
Phase 4 Completed
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT00912340 2018-12-05
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Emory University
Phase 2 Completed
NCT01031446 2018-08-31
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT01797120 2018-05-30
PrE0102
PrECOG, LLC.
Phase 2 Completed
NCT00863655 2017-05-02
BOLERO-2
Novartis
Phase 3 Completed
NCT01007942 2017-04-05
BOLERO-3
Novartis
Phase 3 Completed
NCT00570921 2017-02-23
BRE-43
University of Kentucky
Phase 2 Completed
NCT00499603 2016-11-01
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Unknown
NCT00458237 2016-10-20
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00426556 2015-12-28
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Novartis
Phase 1 Completed
NCT00930930 2015-05-07
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00915603 2014-12-22
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01127763 2014-04-09
RAD001 Plus Carboplatin in Breast Cancer Patients
NYU Langone Health
Phase 2 Completed
NCT00827567 2014-01-13
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Milton S. Hershey Medical Center
Phase 2 Terminated